IL133699A0 - Erbb4 receptor-specific neuregulin, related ligands and uses thereof - Google Patents

Erbb4 receptor-specific neuregulin, related ligands and uses thereof

Info

Publication number
IL133699A0
IL133699A0 IL13369998A IL13369998A IL133699A0 IL 133699 A0 IL133699 A0 IL 133699A0 IL 13369998 A IL13369998 A IL 13369998A IL 13369998 A IL13369998 A IL 13369998A IL 133699 A0 IL133699 A0 IL 133699A0
Authority
IL
Israel
Prior art keywords
domain
neuregulin
nrg3
nucleotide sequences
related ligands
Prior art date
Application number
IL13369998A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL133699A0 publication Critical patent/IL133699A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
IL13369998A 1997-07-09 1998-06-30 Erbb4 receptor-specific neuregulin, related ligands and uses thereof IL133699A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5201997P 1997-07-09 1997-07-09
US08/899,437 US6121415A (en) 1997-07-09 1997-07-24 ErbB4 receptor-specific neuregolin related ligands and uses therefor
PCT/US1998/013411 WO1999002681A1 (en) 1997-07-09 1998-06-30 Erbb4 receptor-specific neuregulin, related ligands and uses thereof

Publications (1)

Publication Number Publication Date
IL133699A0 true IL133699A0 (en) 2001-04-30

Family

ID=26730070

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13369998A IL133699A0 (en) 1997-07-09 1998-06-30 Erbb4 receptor-specific neuregulin, related ligands and uses thereof
IL133699A IL133699A (en) 1997-07-09 1999-12-23 Erbb4 receptor-specific neuregulin, related ligands and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL133699A IL133699A (en) 1997-07-09 1999-12-23 Erbb4 receptor-specific neuregulin, related ligands and uses thereof

Country Status (11)

Country Link
US (6) US6121415A (xx)
EP (1) EP1009826B1 (xx)
JP (2) JP4481485B2 (xx)
AT (1) ATE364080T1 (xx)
AU (1) AU738465B2 (xx)
CA (1) CA2296807C (xx)
DE (1) DE69837884T2 (xx)
ES (1) ES2288764T3 (xx)
IL (2) IL133699A0 (xx)
NZ (1) NZ501915A (xx)
WO (1) WO1999002681A1 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295317A1 (en) * 1997-06-17 1998-12-23 Human Genome Sciences, Inc. Heregulin-like factor
US6727077B1 (en) 1997-06-17 2004-04-27 Human Genome Sciences, Inc. Heregulin-like factor
US7049409B2 (en) * 1997-06-17 2006-05-23 Human Genome Sciences, Inc. Heregulin-like factor antibodies
ZA986077B (en) * 1997-07-09 2000-01-10 Genentech Inc ErbB4 receptor-specific neuregulin related ligands and uses therefor.
US6121415A (en) * 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
WO2000035474A1 (en) * 1998-12-11 2000-06-22 Khurana Tejvir S Neurite derived growth factors for use in the treatment of muscular dystrophy
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
AU6773200A (en) * 1999-08-20 2001-03-19 Chiron Corporation Egfh2 genes and gene products
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US6335190B1 (en) * 2000-10-20 2002-01-01 New England Biolabs, Inc. Method for cloning and producing the BsmI restriction endonuclease in E. coli
US6413758B1 (en) * 2000-10-20 2002-07-02 New England Biolabs, Inc. Method for cloning and expression of Bpml restriction endonuclease in E. coli
IL162844A0 (en) * 2002-01-18 2005-11-20 Inovio As Use of an expression vector for preparing pharmaceutical compositions
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
BRPI0406724A (pt) * 2003-01-13 2005-12-20 Macrogenics Inc Proteìna de fusão dimérica, métodos de tratar, prevenir ou melhorar um ou mais sintomas de um distúrbio autoimune e um ou mais sintomas de púrpura trombocitopênica idiopática, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, método de produzir recombinantemente o polipeptìdeo, polipeptìdeo isolado, fragmento de qualquer um dos polipeptìdeos, e, molécula de ácido nucleico isolada
GB0413005D0 (en) * 2004-06-11 2004-07-14 Coletica Ligand
US7776817B2 (en) 2005-09-02 2010-08-17 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
RU2457854C2 (ru) * 2005-12-30 2012-08-10 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед Длительное высвобождение нейрегулина для улучшения сердечной функции
US20100292209A1 (en) * 2007-03-30 2010-11-18 Massachusetts Institute Of Technology Methods for identifying compounds that modulate neurotrophic factor signaling
US20090291893A1 (en) * 2008-05-23 2009-11-26 Morehouse School Of Medicine Compositions for the prevention and treatment of neuroinjury and methods of use thereof
CA2744512C (en) 2008-11-25 2018-05-15 Genentech, Inc. Isoform specific anti-her4 antibodies
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
US20130058871A1 (en) * 2011-07-28 2013-03-07 Howard Hughes Medical Institute Method and system for mapping synaptic connectivity using light microscopy
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2014051567A1 (en) * 2012-09-26 2014-04-03 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
EP3075846B1 (en) 2013-11-27 2020-09-16 Kaneka Corporation Cell culture medium and culture method using the same
US20210355448A1 (en) * 2017-06-26 2021-11-18 City Of Hope Methods of islet cell culture
RU2682175C1 (ru) * 2018-07-04 2019-03-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики посттравматической и идиопатической эпилепсии

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
CA2109085C (en) * 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US6087323A (en) * 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
IL105914A0 (en) * 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
DE69430824T2 (de) * 1993-08-12 2003-01-23 Neurotech Sa Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
CA2217020A1 (en) * 1995-05-16 1996-11-21 Bristol-Myers Squibb Company Recombinant heregulins and their biological functions upon receptor activation
US5912326A (en) * 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
CA2295317A1 (en) 1997-06-17 1998-12-23 Human Genome Sciences, Inc. Heregulin-like factor
US6727077B1 (en) * 1997-06-17 2004-04-27 Human Genome Sciences, Inc. Heregulin-like factor
US7049409B2 (en) * 1997-06-17 2006-05-23 Human Genome Sciences, Inc. Heregulin-like factor antibodies
US6121415A (en) * 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor

Also Published As

Publication number Publication date
DE69837884T2 (de) 2008-02-07
US20050136467A1 (en) 2005-06-23
ES2288764T3 (es) 2008-01-16
US20070048822A1 (en) 2007-03-01
JP2003517260A (ja) 2003-05-27
ATE364080T1 (de) 2007-06-15
CA2296807A1 (en) 1999-01-21
IL133699A (en) 2007-03-08
AU8173498A (en) 1999-02-08
AU738465B2 (en) 2001-09-20
WO1999002681A1 (en) 1999-01-21
NZ501915A (en) 2002-08-28
US7846453B2 (en) 2010-12-07
US6252051B1 (en) 2001-06-26
US6121415A (en) 2000-09-19
JP2009077716A (ja) 2009-04-16
US20030036166A1 (en) 2003-02-20
US20020161200A1 (en) 2002-10-31
CA2296807C (en) 2011-08-23
EP1009826B1 (en) 2007-06-06
JP4481485B2 (ja) 2010-06-16
EP1009826A1 (en) 2000-06-21
DE69837884D1 (de) 2007-07-19

Similar Documents

Publication Publication Date Title
IL133699A0 (en) Erbb4 receptor-specific neuregulin, related ligands and uses thereof
AU5481890A (en) Fibronectin binding protein as well as its preparation
NZ515913A (en) Modified chimeric polypeptides with improved pharmacokinetic properties
AU3498189A (en) Fibronectin binding protein
AU6860396A (en) Purified coprinus laccases and nucleic acids encoding same
AU1691588A (en) A fibronectin binding protein as well as its preparation
AU2990997A (en) Type C lectins
WO2000026370A3 (en) Adenine nucleotide translocator (ant) fusion proteins and uses thereof
EP0546087A4 (xx)
CA2071950A1 (en) Collagen binding protein as well as its preparation
GB9820003D0 (en) Novel compounds
GB9809683D0 (en) Novel compounds
PL345193A1 (en) Basb027 proteins and genes from moraxella catarrhalis
AU4504999A (en) Novel compounds
GB9810285D0 (en) Novel compounds
AU4505099A (en) (moraxella catarrahalis) polynucleotides and polypeptides
DE60026049D1 (de) POLYPEPTIDE MIT GLUCANOTRANSFERASE AKTIVITÄT UND DAFüR KODIERENDE NUKLEINSÄUREN
AU3787499A (en) Semaphorin polypeptides
AU3667397A (en) Recombinant n-proteinase, and the production, methods and uses thereof
HK1047956A1 (zh) Basb118多肽和來自黏膜炎莫拉氏菌多核苷酸
AU6988700A (en) Basb119 polypeptide and polynucleotide from moraxella catarrhalis
EP0906957A3 (en) Lgt polypeptide
AU4260299A (en) Basb028 polypeptides and polynucleotides encoding therefor from moraxella catarrhalis
EP1159421B8 (en) Human suppressor of fused
HK1045331A1 (en) Basb111 polypeptide and polynucleotide from moraxella catharrhalis

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed